Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands

Background The aim of the present study was to estimate the effectiveness of the MF59™-adjuvanted influenza A(H1N1)pdm09 vaccine against medically attended influenza-like illness and RT-PCR confirmed influenza in the at-risk population and persons over 60 in the Netherlands. Methods We conducted a retrospective cohort study in a Dutch based GP medical record database between 30 November 2009 and 1 March 2010 to estimate the vaccine effectiveness against influenza-like illness. Within the cohort we nested a test negative case-control study to estimate the effectiveness against laboratory confirmed influenza. Results The crude effectiveness in preventing diagnosed or possible influenza-like illness was 17.3% (95%CI: −8.5%–36.9%). Of the measured covariates, age, the severity of disease and health seeking behaviour through devised proxies confounded the association between vaccination and influenza-like illness. The adjusted vaccine effectiveness was 20.8% (95%CI: −5.4%, 40.5%) and varied significantly by age, being highest in adults up to 50 years (59%, 95%CI: 23%, 78%), and non-detectable in adults over 50 years. The number of cases in the nested case control study was too limited to validly estimate the VE against confirmed influenza. Conclusions With our study we demonstrated that the approach of combining a cohort study in a primary health care database with field sampling is a feasible and useful option to monitor VE of influenza vaccines in the future.

[1]  M. Valenciano,et al.  Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study , 2011, PLoS medicine.

[2]  J. Castilla,et al.  Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: cohort and case-control study. , 2011, Vaccine.

[3]  Alberto Arnedo-Pena,et al.  Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. , 2010, Vaccine.

[4]  A. Ortqvist,et al.  Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  W Carman,et al.  Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  J. Noh,et al.  Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. , 2011, Vaccine.

[7]  J H van Bemmel,et al.  Postmarketing Surveillance Based on Electronic Patient Records: The IPCI Project , 1999, Methods of Information in Medicine.

[8]  A. Monto,et al.  Influenza Control in the 21st Century: Optimizing Protection of Older Adults , 2022 .

[9]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[10]  T. Vega,et al.  Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010 , 2011, BMC public health.

[11]  Colin Simpson,et al.  Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. , 2010, Health technology assessment.

[12]  N. Andrews,et al.  Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England , 2011, The Journal of infectious diseases.

[13]  D. Skowronski,et al.  Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009 , 2011, BMJ : British Medical Journal.

[14]  U. Buchholz,et al.  Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10 , 2011, PloS one.

[15]  Colin Simpson,et al.  Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study. , 2012, The Lancet. Infectious diseases.

[16]  F. Carrat,et al.  Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France , 2011, PloS one.

[17]  B. Stricker,et al.  Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia. , 2006, Archives of internal medicine.

[18]  G. Poggensee,et al.  Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  J. Dieleman,et al.  Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study , 2011, BMC infectious diseases.

[20]  J H van Bemmel,et al.  The Introduction of Computer-based Patient Records in the Netherlands , 1993, Annals of Internal Medicine.

[21]  K. Johansen,et al.  Pandemic influenza A(H1N1) 2009 vaccines in the European Union. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[22]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.